Literature DB >> 10601439

Nicotine modulates evoked GABAergic transmission in the brain.

P J Zhu1, V A Chiappinelli.   

Abstract

The effects of nicotine on evoked GABAergic synaptic transmission were examined using whole cell recordings from neurons of the lateral spiriform nucleus in embryonic chick brain slices. All synaptic activities were abolished by the GABA(A) receptor antagonist, bicuculline (20 microM). Under voltage-clamp with KCl-filled pipettes (holding potential -70 mV), nicotine (0.1-1.0 microM) increased the frequency of spontaneous GABAergic currents in a dose-dependent manner. Nicotine enhanced electrically evoked GABAergic transmission only at relatively low concentrations of 50-100 nM (but not 25 nM), which approximate the concentrations of nicotine in the blood produced by cigarette smoking. At higher concentrations nicotine had either no effect (0.25 microM) or diminished (0.5-1.0 microM) evoked GABAergic neurotransmission. Nicotine had no significant effect on the postsynaptic current induced by exogenous GABA (30-50 microM). These data imply that nicotine levels attained in smokers are sufficient to enhance evoked GABAergic transmission in the brain, and that this effect is most likely mediated through activation of presynaptic nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601439     DOI: 10.1152/jn.1999.82.6.3041

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  14 in total

1.  A study of the acute effect of smoking on cerebral blood flow using 99mTc-ECD SPET.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Toshihide Monden; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-15       Impact factor: 9.236

Review 2.  Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors.

Authors:  Bruce E McKay; Andon N Placzek; John A Dani
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  Recent advances in gene manipulation and nicotinic acetylcholine receptor biology.

Authors:  Anne Tammimäki; William J Horton; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2011-06-16       Impact factor: 5.858

4.  Nicotine excites hypothalamic arcuate anorexigenic proopiomelanocortin neurons and orexigenic neuropeptide Y neurons: similarities and differences.

Authors:  Hao Huang; Youfen Xu; Anthony N van den Pol
Journal:  J Neurophysiol       Date:  2011-06-08       Impact factor: 2.714

5.  Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.

Authors:  Stanley D Glick; Elizabeth M Sell; Sarah E McCallum; Isabelle M Maisonneuve
Journal:  Eur J Pharmacol       Date:  2011-08-19       Impact factor: 4.432

6.  Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats.

Authors:  M N Lipovac; A Hashim; H Sershen; D Allen; T Cooper; P Czobor; A Lajtha
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

7.  The effects of glutamate and GABA receptor antagonists on nicotine-induced neurotransmitter changes in cognitive areas.

Authors:  S Fallon; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2006-08-15       Impact factor: 3.996

8.  Cholinergic modulation of appetite-related synapses in mouse lateral hypothalamic slice.

Authors:  Young-Hwan Jo; Denise Wiedl; Lorna W Role
Journal:  J Neurosci       Date:  2005-11-30       Impact factor: 6.167

Review 9.  Prenatal nicotine exposure and development of nicotinic and fast amino acid-mediated neurotransmission in the control of breathing.

Authors:  Ralph F Fregosi; Jason Q Pilarski
Journal:  Respir Physiol Neurobiol       Date:  2008-12-10       Impact factor: 1.931

10.  Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration.

Authors:  Stanley D Glick; Elizabeth M Sell; Isabelle M Maisonneuve
Journal:  Eur J Pharmacol       Date:  2008-10-01       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.